🔎 Trials Near Me

Pradžia › ŽIV › Džordžija

ŽIV klinikiniai tyrimai Džordžija

14 tyrimai dėl ŽIV ieško dalyvių vietose Džordžija.

Miestai Džordžija

Oficialus tyrimo tekstas (anglų kalba)

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

  • Faebris Medical & Community Education, Atlanta
  • Grady Memorial Hospital, Atlanta
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07473778

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  • GSK Investigational Site, Decatur
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07650916

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  • Metro Infectious Diseases Consultants L.L.C. ( Site 1509), Decatur
  • Mercer university, Department of internal medicine-Clinical Research ( Site 1512), Macon
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07266831

Screen2Prevent (S2P)

  • Emory Atlanta Adolescent Consortium, Atlanta
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 14 iki 24 · Visoms lytims · Atnaujinta 2026-08-17 · NCT07728123

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  • Atlanta ID Group, PC, Atlanta
  • Chatham County Health Department, Savannah
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-14 · NCT07682961

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  • GSK Investigational Site, Atlanta
  • GSK Investigational Site, Macon
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-23 · NCT07202546

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

  • Emory Children's Center ( Site 0103), Atlanta
Renkami dalyviai2 fazė
4 Weeks – 11 Years · Visoms lytims · Atnaujinta 2026-07-08 · NCT04375800

Inflammation and Depression in People With HIV

  • Grady Memorial Hospital, Atlanta
  • Emory University Hospital, Atlanta
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-05-28 · NCT05849038

Menopausal HT for Women Living With HIV (HoT)

  • The Ponce de Leon Center CRS (5802), Atlanta
Renkami dalyviai4 fazė
Amžius nuo 40 iki 60 · Moterims · Atnaujinta 2026-05-22 · NCT06856174

Low Dose Naltrexone for Pain in Patients With HIV

  • Grady Memorial Hospital, Atlanta
  • Emory Midtown Hospital, Atlanta
  • Emory University Hospital, Atlanta
Renkami dalyviai4 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-04-09 · NCT05537935

Baricitinib for Reduction of HIV - CNS

  • Grady Memorial Hospital, Atlanta
  • Emory University Hospital, Atlanta
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-03-23 · NCT05452564

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

  • Ponce de Leon Center CRS, Atlanta
  • The Hope Clinic of the Emory Vaccine Research Center; Emory University, Decatur
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 55 · Visoms lytims · Atnaujinta 2025-09-25 · NCT06796686

HIV Treatment Adherence Dose Determination Trial

  • University of Connecticut Field Site, Atlanta
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-08-29 · NCT04577313

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

  • GSK Investigational Site, Atlanta
Renkami dalyviai1/2 fazė
Amžius nuo 6 iki 12 · Visoms lytims · Atnaujinta 2024-09-19 · NCT05674656

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.